REG - RTW Biotech Opp. - RTW CIO increases position to 15%

RTW Biotech OpportunitiesAnnouncement

26/02/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250226:nRSZ4504Ya&default-theme=true

RNS Number : 4504Y  RTW Biotech Opportunities Ltd  26 February 2025

LEI: 549300Q7EXQQH6KF7Z84

26 February 2025

RTW Biotech Opportunities Ltd

RTW CIO increases position to 15%

 

RTW Biotech Opportunities Ltd (the "Company", "RTW Bio"), a London Stock
Exchange-listed investment company focused on identifying transformative
assets with high growth potential across the life sciences sector, is pleased
to note the purchase by the CIO of its Investment Manager, Rod Wong, of
additional shares bringing his total shareholding to 15.00%. Over the last
year, he has acquired 20,663,008 shares in the market following the completion
of the Arix transaction.

 

Roderick Wong, Managing Partner and CIO at RTW Investments, LP, the Investment
Manager commented: "I believe that now is a once-in-cycle opportunity to make
private and public investments in biotech, so I am excited to increase my
personal holdings in the Company. The listed investment company structure is
ideal for private to public healthcare investing, exemplified by the
opportunity we currently see in next-generation obesity therapies. With our
investments in Corxel and Kailera, we believe that RTW Bio is uniquely
positioned among listed investment companies to benefit from continued
innovation in the area. Metsera's recent successful IPO points to the strong
interest for promising new obesity products."

 

William Simpson, Chair of the Board of the Company commented: "We are
delighted that our Investment Manager's CIO, Rod Wong, has continued to
personally buy shares in the open market. This further emphasises RTW
Investments' commitment to and alignment with the Company and underscores
their strong belief that the Company's shares are undervalued."

 

 

For Further Information

 RTW Investments, LP                                                      +44 20 7959 6361
 Woody Stileman, Managing Director, Business Development                  biotechopportunities@rtwfunds.com (mailto:biotechopportunities@rtwfunds.com)

 Krisha McCune, Director, Investor Relations

 Cadarn Capital (PR & Communications/Distribution & IR Partner)           +44 79 8418 4461
                                                                           Lucy@cadarncapital.com (mailto:Lucy@cadarncapital.com)

 Lucy Clark (PR)

 David Harris (Distribution)                                              +44 73 6888 3211

                                                                          david@cadarncapital.com

 Deutsche Numis (Joint Corporate Broker)                                  +44 20 7260 1000

 Freddie Barnfield

 Nathan Brown

 Euan Brown

 BofA Securities (Joint Corporate Broker)                                 +44 20 7628 1000

 Edward Peel

 Alex Penney

 Altum (Guernsey) Limited (formerly named Elysium Fund Management Ltd)     +44 14 8170 3100

 Joanna Duquemin Nicolle, Director

 Sadie Morrison, Director

 Morgan Stanley Fund Services USA LLC                                     +1 914 225 8885

About Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

***********

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAFASAAXSEAA